CMED Aesthetics

CMed Aesthetics S.p.A. is an Italian company specializing in aesthetic medicine, dermatology, and plastic surgery. Founded in August 2017 by Carlo Michellini and Andrea Malventi, the company is headquartered in Pisa, Italy. The founders, both chemists who graduated from Pisa University, established the company to merge pharmaceutical expertise with commercial application in the aesthetics field.

The company develops and markets a range of products for professional use, including patented medical devices and cosmeceuticals. Its portfolio includes mesotherapy solutions, depigmenting treatments, and a notable dermal peel system called BioReTherapy, which features the core product BioRePeelCl3®. This product is based on a patented bi-phasic technology that combines exfoliating, revitalizing, and biostimulating effects. CMed Aesthetics also holds patents for a novel sterilization technology (NTS®) that preserves the integrity of thermolabile substances like hyaluronic acid by avoiding heat-based degradation. The company's products are manufactured in Italy and distributed globally, with a presence in over 80 countries.

CMed Aesthetics operates on a business-to-business model, serving healthcare professionals, clinics, and distributors worldwide. The company adheres to stringent pharmaceutical and international quality standards, holding ISO 13485 and ISO 22716 certifications. Its revenue has shown significant growth, reaching €9.02 million in 2023. The company has received investment from firms including Azimut Holding and Electa Ventures.

Keywords: aesthetic medicine, dermatology, medical devices, bi-phasic technology, dermal peel, BioRePeelCl3, professional skincare, cosmeceuticals, plastic surgery, non-thermal sterilization, mesotherapy, skincare innovation, Italian skincare, pharmaceutical standards, ISO 13485, aesthetic treatments, regenerative aesthetics, skin revitalization, professional peels, global distribution